Tag:
epigenetics
Latest Headlines
Latest Headlines
Blood test for bowel cancer is in the DNA
Classic testing for bowel cancer involves a fecal sample--not much fun for the patient or for the lab staff. A study from Australia has looked at DNA methylation as a possible colorectal cancer blood test and a more straightforward and user-friendly route to diagnosis.
Epigenetics signal possible breast cancer blood test
Epigenetic changes (genetic changes that do not affect the DNA sequence) could be associated with the development of breast cancer, and may lead to a blood biomarker-based test.
Epizyme builds epigenetics lineup with $90M Celgene score
The pact includes a commitment to pay tens of millions more in milestones for any successful therapies that come out of the deal.
DNA methylation may be breast cancer marker
In DNA methylation, small chemical groups are tagged on to the DNA to control expression. This can be used to suppress viral DNA, or to modify normal gene expression. DNA methylation is also involved...
Constellation inks $95M discovery deal, buyout option with Genentech
Epigenetics is a new field in drug discovery. But one of the pioneers of the science has already struck a lucrative partnership pact with Roche's Genentech that could pave the way to a buyout.
Fast-growing Forma grabs $815M cancer discovery deal with Boehringer
Forma Therapeutics has nabbed an $815 million deal--$65 million of that in an upfront payment and the rest in pre-commercial milestones--to direct its growing drug discovery engine to new small
GSK's epigenetics team tests promising leukemia drug in mice
One of the chief culprits behind infant leukemia, and a significant number of adult cases, is a fusion protein involving MLL which triggers genes that drive the development of cancer. Proteins from
Big Pharma pursues epigenetics for cancer breakthroughs
Big Pharma companies like GlaxoSmithKline, Eli Lilly and Novartis are among the drugmakers pursuing new cancer treatments based on epigenetics--an approach that aims to reprogram abnormal DNA that
Epizyme making big plans for pioneering epigenetics platform
Xconomy's Luke Timmerman spent some time with the CEO and CBO at Epizyme to see how the three-year-old biotech was able to score two impressive development deals with Big Pharma earlier this year.
Investigators herald new approach to next-gen cancer drugs
Scientists at the Dana-Farber Cancer Institute say they created a new molecule that scrambled the internal communications system for cancer cells, underscoring the potential of epigenetic "reader"
